[go: up one dir, main page]

WO2008031501A3 - 2-phenoxynikotinsäure-derivate und ihre verwendung - Google Patents

2-phenoxynikotinsäure-derivate und ihre verwendung Download PDF

Info

Publication number
WO2008031501A3
WO2008031501A3 PCT/EP2007/007575 EP2007007575W WO2008031501A3 WO 2008031501 A3 WO2008031501 A3 WO 2008031501A3 EP 2007007575 W EP2007007575 W EP 2007007575W WO 2008031501 A3 WO2008031501 A3 WO 2008031501A3
Authority
WO
WIPO (PCT)
Prior art keywords
phenoxy
acid derivative
nicotine acid
prophylaxis
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/007575
Other languages
English (en)
French (fr)
Other versions
WO2008031501A2 (de
Inventor
Heinrich Meier
Peter Kolkhof
Axel Kretschmer
Arounarith Tuch
Lars BÄRFACKER
Yolanda Cancho Grande
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Priority to US12/440,725 priority Critical patent/US20100298221A1/en
Priority to JP2009527717A priority patent/JP2010507569A/ja
Priority to EP07801996A priority patent/EP2066635A2/de
Priority to CA002662879A priority patent/CA2662879A1/en
Publication of WO2008031501A2 publication Critical patent/WO2008031501A2/de
Anticipated expiration legal-status Critical
Publication of WO2008031501A3 publication Critical patent/WO2008031501A3/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die vorliegende Anmeldung betrifft 2-Phenoxy-6-phenyl- und 2- Phenoxy-6-pyridylnikotinsäure-Derivate der allgemeinen Formel (I). Verfahren zu ihrer Herstellung, ihre Verwendung zur Behandlung und/oder Prophylaxe von Krankheiten sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prophylaxe von Krankheiten, vorzugsweise zur Behandlung und/oder Prophylaxe kardiovaskulärer Erkrankungen, insbesondere von Dyslipidämien, Arteriosklerose und Herzinsuffizienz.
PCT/EP2007/007575 2006-09-12 2007-08-30 2-phenoxynikotinsäure-derivate und ihre verwendung Ceased WO2008031501A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/440,725 US20100298221A1 (en) 2006-09-12 2007-08-30 2-phenoxy nicotine acid derivative and use thereof
JP2009527717A JP2010507569A (ja) 2006-09-12 2007-08-30 ２−フェノキシニコチン酸誘導体およびそれらの使用
EP07801996A EP2066635A2 (de) 2006-09-12 2007-08-30 2-phenoxynikotinsäure-derivate und ihre verwendung
CA002662879A CA2662879A1 (en) 2006-09-12 2007-08-30 2-phenoxynicotinic acid derivatives and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006043520.6 2006-09-12
DE102006043520A DE102006043520A1 (de) 2006-09-12 2006-09-12 2-Phenoxynikotinsäure-Derivate und ihre Verwendung

Publications (2)

Publication Number Publication Date
WO2008031501A2 WO2008031501A2 (de) 2008-03-20
WO2008031501A3 true WO2008031501A3 (de) 2011-04-14

Family

ID=38681456

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/007575 Ceased WO2008031501A2 (de) 2006-09-12 2007-08-30 2-phenoxynikotinsäure-derivate und ihre verwendung

Country Status (11)

Country Link
US (1) US20100298221A1 (de)
EP (1) EP2066635A2 (de)
JP (1) JP2010507569A (de)
AR (1) AR062586A1 (de)
CA (1) CA2662879A1 (de)
CL (1) CL2007002637A1 (de)
DE (1) DE102006043520A1 (de)
PE (1) PE20081371A1 (de)
TW (1) TW200829553A (de)
UY (1) UY30582A1 (de)
WO (1) WO2008031501A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007042754A1 (de) 2007-09-07 2009-03-12 Bayer Healthcare Ag Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
EA030839B1 (ru) 2011-10-28 2018-10-31 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
MX382960B (es) 2011-10-28 2025-03-13 Shire Human Genetic Therapies Inhibidores de la recirculación de ácidos biliares para el tratamiento de hipercolemia y enfermedad hepática colestásica.
KR20230152818A (ko) 2013-03-15 2023-11-03 샤이어 휴먼 지네틱 테라피즈 인크. 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
CA2907214A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
AU2020221834B2 (en) 2019-02-12 2025-10-23 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an ASBTI in patients with bile salt export pump deficiency

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082191A2 (en) * 2002-03-28 2003-10-09 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005027150A1 (de) * 2005-03-12 2006-09-28 Bayer Healthcare Ag Pyrimidincarbonsäure-Derivate und ihre Verwendung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082191A2 (en) * 2002-03-28 2003-10-09 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines

Also Published As

Publication number Publication date
WO2008031501A2 (de) 2008-03-20
UY30582A1 (es) 2008-05-02
JP2010507569A (ja) 2010-03-11
CA2662879A1 (en) 2008-03-20
DE102006043520A1 (de) 2008-03-27
AR062586A1 (es) 2008-11-19
PE20081371A1 (es) 2008-10-16
US20100298221A1 (en) 2010-11-25
TW200829553A (en) 2008-07-16
CL2007002637A1 (es) 2008-03-14
EP2066635A2 (de) 2009-06-10

Similar Documents

Publication Publication Date Title
WO2008104306A3 (de) Substituierte 4-aryl-1,4-dihydro-1,6-naphthyridinamide und ihre verwendung
WO2008113469A8 (de) Substituierte imidazo- und triazolopyrimidine
WO2009145456A3 (ko) 헤테로사이클 유도체
WO2009018816A3 (de) Verbesserte arzneimittelbeschichtete medizinprodukte, deren herstellung und verwendung
WO2009068214A3 (de) Heteroaryl-substituierte piperidine
WO2008119457A3 (de) Lactam-substituierte dicarbonsäuren und ihre verwendung
WO2010037066A3 (en) Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2008031501A3 (de) 2-phenoxynikotinsäure-derivate und ihre verwendung
WO2009033561A8 (de) Substituierte 6-phenylnikotinsäuren und ihre verwendung
JO2756B1 (en) The second preparation of aqueous pyrimidnon containing 4- (4-ciano-2-2 thiourail) and its use)
WO2012076466A3 (de) Substituierte 1-benzylcycloalkylcarbonsäuren und ihre verwendung
TN2011000466A1 (en) Substituted 2-acetamido -5-aryl-1, 2, 4- triazolones and use thereof
WO2008046581A3 (de) Substituierte tetrahydropyrrolopyrazin-verbindungen als inhibitoren der monoaminwiederaufnahme und deren verwendung in arzeimitteln
WO2008155069A3 (de) Substituierte oxazolidinone und ihre verwendung
WO2009076141A3 (en) Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cycklopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
TW200736213A (en) Dicarboxylic acid derivatives and their use
ATE523510T1 (de) Substituierte 4-aryl-1,4-dihydro-1,6- naphthyridine und ihre verwendung
WO2010078900A3 (de) Neue aliphatisch substituierte pyrazolopyridine und ihre verwendung
IL216967A0 (en) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases
WO2009074247A8 (de) Neue 2-aryl-thiazol-4-carbonsäureamid-derivate, deren herstellung und verwendung als arzneimittel
UA102238C2 (en) 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof
WO2009080006A3 (de) Neuer mariendistelextrakt, verfahren zur herstellung und verwendung
WO2011009533A3 (de) 17-hydroxy-17-pentafluorethyl-estra-4,9(10) -dien-11-ethinylphenyl-derivate, verfahren zu deren herstellung und deren verwendung zur behandlung von krankheiten
MX2011012505A (es) Piperidinas sustituidas.
MY142036A (en) New quaternized quinuclidine esters

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07801996

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007801996

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2662879

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009527717

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12440725

Country of ref document: US